AGEN 1531
Alternative Names: AGEN-1531Latest Information Update: 28 Apr 2024
Price :
$50 *
At a glance
- Originator Agenus
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 01 Apr 2020 AGEN 1531 is available for licensing as of 01 Apr 2020. https://agenusbio.com/
- 31 Mar 2020 Preclinical trials in Cancer in USA (Parenteral) (Agenus pipeline, March 2020)